IGNITE: Implementing GeNomics In practice: Genomic Medicine Implementation - The Personalized Medicine Program

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update

Julie A. Johnson, K. Caudle, L. Gong, et al.. (2017). Clinical Pharmacology & Therapeutics. Cited 571 times. https://doi.org/10.1002/cpt.668

Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.

L. Cavallari, Craig R. Lee, A. Beitelshees, et al.. (2018). JACC. Cardiovascular interventions. Cited 270 times. https://doi.org/10.1016/j.jcin.2017.07.022

Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine

Nihal El Rouby, J. Lima, Julie A. Johnson. (2018). Expert Opinion on Drug Metabolism & Toxicology. Cited 223 times. https://doi.org/10.1080/17425255.2018.1461835

Clinical pharmacogenetics implementation: Approaches, successes, and challenges

K. Weitzel, Amanda R. Elsey, T. Langaee, et al.. (2014). American Journal of Medical Genetics Part C: Seminars in Medical Genetics. Cited 198 times. https://doi.org/10.1002/ajmg.c.31390

Warfarin pharmacogenetics.

Julie A. Johnson, L. Cavallari. (2015). Trends in cardiovascular medicine. Cited 169 times. https://doi.org/10.1016/j.tcm.2014.09.001

The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems

Jasmine A. Luzum, R. Pakyz, Amanda R. Elsey, et al.. (2017). Clinical Pharmacology & Therapeutics. Cited 137 times. https://doi.org/10.1002/cpt.630

Pharmacogenetics and Cardiovascular Disease—Implications for Personalized Medicine

Julie A. Johnson, L. Cavallari. (2013). Pharmacological Reviews. Cited 134 times. https://doi.org/10.1124/pr.112.007252

Emerging Roles for Pharmacists in Clinical Implementation of Pharmacogenomics

A. Owusu-Obeng, K. Weitzel, R. Hatton, et al.. (2014). Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. Cited 120 times. https://doi.org/10.1002/phar.1481

CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial

D. M. Smith, K. Weitzel, Amanda R. Elsey, et al.. (2019). Genetics in medicine : official journal of the American College of Medical Genetics. Cited 119 times. https://doi.org/10.1038/s41436-018-0431-8

Implementing Personalized Medicine: Development of a Cost‐Effective Customized Pharmacogenetics Genotyping Array

J. A. Johnson, B. Burkley, T. Langaee, et al.. (2012). Clinical Pharmacology & Therapeutics. Cited 117 times. https://doi.org/10.1038/clpt.2012.125

Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype‐Guided Antiplatelet Therapy

P. Empey, J. Stevenson, S. Tuteja, et al.. (2018). Clinical Pharmacology & Therapeutics. Cited 114 times. https://doi.org/10.1002/cpt.1006

Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics.

Julie A. Johnson, Amanda R. Elsey, M. Clare-Salzler, et al.. (2013). Pharmacogenomics. Cited 91 times. https://doi.org/10.2217/pgs.13.59

Hypertension pharmacogenomics: in search of personalized treatment approaches

R. Cooper-DeHoff, Julie A. Johnson. (2016). Nature Reviews Nephrology. Cited 90 times. https://doi.org/10.1038/nrneph.2015.176

Educational strategies to enable expansion of pharmacogenomics-based care.

K. Weitzel, C. Aquilante, Samuel G. Johnson, et al.. (2016). American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. Cited 85 times. https://doi.org/10.2146/AJHP160104

Implementing Pharmacogenomics at Your Institution: Establishment and Overcoming Implementation Challenges

Meghan J. Arwood, Supatat Chumnumwat, Larisa H. Cavallari, et al.. (2016). Clinical and Translational Science. Cited 85 times. https://doi.org/10.1111/cts.12404

The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real‐World Setting

L. Cavallari, A. Beitelshees, K. Blake, et al.. (2017). Clinical and Translational Science. Cited 82 times. https://doi.org/10.1111/cts.12456

Preemptive Panel-Based Pharmacogenetic Testing: The Time is Now

K. Weitzel, L. Cavallari, L. Lesko. (2017). Pharmaceutical Research. Cited 77 times. https://doi.org/10.1007/s11095-017-2163-x

Pharmacogenetics in clinical practice: how far have we come and where are we going?

Julie A. Johnson. (2013). Pharmacogenomics. Cited 75 times. https://doi.org/10.2217/pgs.13.52

Institutional profile: University of Florida Health Personalized Medicine Program.

L. Cavallari, K. Weitzel, Amanda R. Elsey, et al.. (2017). Pharmacogenomics. Cited 67 times. https://doi.org/10.2217/pgs-2017-0028

Pharmacogenomics competencies in pharmacy practice: A blueprint for change.

Mary W. Roederer, G. Kuo, D. Kisor, et al.. (2017). Journal of the American Pharmacists Association : JAPhA. Cited 67 times. https://doi.org/10.1016/j.japh.2016.08.014

Role of genetic testing in patients undergoing percutaneous coronary intervention

J. Moon, Francesco Franchi, F. Rollini, et al.. (2018). Expert Review of Clinical Pharmacology. Cited 66 times. https://doi.org/10.1080/17512433.2017.1353909

Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene–drug pairs across ambulatory care settings

Emily J. Cicali, K. Weitzel, Amanda R. Elsey, et al.. (2019). Genetics in Medicine. Cited 62 times. https://doi.org/10.1038/s41436-019-0500-7

Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing

L. Cavallari, S. L. Driest, C. Prows, et al.. (2019). Genetics in medicine : official journal of the American College of Medical Genetics. Cited 60 times. https://doi.org/10.1038/s41436-019-0484-3

Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention

L. Cavallari, Francesco Franchi, F. Rollini, et al.. (2018). Journal of Translational Medicine. Cited 58 times. https://doi.org/10.1186/s12967-018-1469-8

Advancing Pharmacogenomics as a Component of Precision Medicine: How, Where, and Who?

Ja Johnson, K. Weitzel. (2016). Clinical Pharmacology & Therapeutics. Cited 52 times. https://doi.org/10.1002/cpt.273

Implementation of inpatient models of pharmacogenetics programs.

L. Cavallari, Craig R. Lee, Julio D. Duarte, et al.. (2016). American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. Cited 46 times. https://doi.org/10.2146/AJHP150946

Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections

Issam S. Hamadeh, K. Klinker, Samuel J. Borgert, et al.. (2017). Pharmacogenetics and Genomics. Cited 45 times. https://doi.org/10.1097/FPC.0000000000000277

Qualitative study of system level factors related to genomic implementation

A. Zebrowski, Darcy E. Ellis, F. Barg, et al.. (2018). Genetics in medicine : official journal of the American College of Medical Genetics. Cited 43 times. https://doi.org/10.1038/s41436-018-0378-9

Effects of Using Personal Genotype Data on Student Learning and Attitudes in a Pharmacogenomics Course

K. Weitzel, C. McDonough, Amanda R. Elsey, et al.. (2016). American Journal of Pharmaceutical Education. Cited 39 times. https://doi.org/10.5688/ajpe807122

Implementation of Standardized Clinical Processes for TPMT Testing in a Diverse Multidisciplinary Population: Challenges and Lessons Learned

Kristin W. Weitzel, D. M. Smith, Amanda R. Elsey, et al.. (2018). Clinical and Translational Science. Cited 33 times. https://doi.org/10.1111/cts.12533

A Novel Simple Method for Determining CYP2D6 Gene Copy Number and Identifying Allele(s) with Duplication/Multiplication

T. Langaee, Issam S. Hamadeh, A. Chapman, et al.. (2015). PLoS ONE. Cited 31 times. https://doi.org/10.1371/journal.pone.0113808

Pharmacogenetics: Using Genetic Information to Guide Drug Therapy.

Ku-Lang Chang, K. Weitzel, S. Schmidt. (2015). American family physician. Cited 29 times.

Novel Implementation of Genotype‐Guided Proton Pump Inhibitor Medication Therapy in Children: A Pilot, Randomized, Multisite Pragmatic Trial

Emily J. Cicali, K. Blake, Y. Gong, et al.. (2018). Clinical and Translational Science. Cited 29 times. https://doi.org/10.1111/cts.12589

Clinical application of pharmacogenetics in pain management.

D. M. Smith, K. Weitzel, L. Cavallari, et al.. (2018). Personalized medicine. Cited 28 times. https://doi.org/10.2217/pme-2017-0032

Pharmacogenomics of Hypertension and Heart Disease

Meghan J. Arwood, L. Cavallari, Julio D. Duarte. (2015). Current Hypertension Reports. Cited 27 times. https://doi.org/10.1007/s11906-015-0586-5

Genetics of Resistant Hypertension: a Novel Pharmacogenomics Phenotype

N. Rouby, R. Cooper-DeHoff. (2015). Current Hypertension Reports. Cited 25 times. https://doi.org/10.1007/s11906-015-0583-8

Is universal HLA‐B*15:02 screening a cost‐effective option in an ethnically diverse population? A case study of Malaysia

H. Chong, Zahurin Mohamed, Leng Leng Tan, et al.. (2017). British Journal of Dermatology. Cited 20 times. https://doi.org/10.1111/bjd.15498

Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for tamoxifen pharmacogenetic studies.

Julie A. Johnson, Issam S. Hamadeh, T. Langaee. (2015). Journal of the National Cancer Institute. Cited 18 times. https://doi.org/10.1093/jnci/dju437

Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial.

Scott A. Mosley, J. K. Hicks, D. Portman, et al.. (2018). Contemporary clinical trials. Cited 15 times. https://doi.org/10.1016/j.cct.2018.03.001

Genetic Determinants of P2Y12 Inhibitors and Clinical Implications.

L. Cavallari, A. Obeng. (2017). Interventional cardiology clinics. Cited 14 times. https://doi.org/10.1016/j.iccl.2016.08.010

The influence of the CYP2C1910 allele on clopidogrel activation and CYP2C192 genotyping

T. Langaee, Hao‐Jie Zhu, Xinwen Wang, et al.. (2014). Pharmacogenetics and Genomics. Cited 13 times. https://doi.org/10.1097/FPC.0000000000000068

Clinical Implementation of Pharmacogenetics: More than One Gene at a Time

J. A. Johnson, T. Klein, M. Relling. (2013). Clinical Pharmacology & Therapeutics. Cited 13 times. https://doi.org/10.1038/clpt.2013.7

Cardiovascular Pharmacogenomics--Implications for Patients With CKD.

L. Cavallari, Darius L. Mason. (2016). Advances in chronic kidney disease. Cited 12 times. https://doi.org/10.1053/j.ackd.2015.12.001

Time to revisit warfarin pharmacogenetics.

L. Cavallari. (2017). Future cardiology. Cited 10 times. https://doi.org/10.2217/fca-2017-0061

Pharmacogenomics in cardiology--genetics and drug response: 10 years of progress.

L. Cavallari, K. Weitzel. (2015). Future cardiology. Cited 10 times. https://doi.org/10.2217/fca.15.20

Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention

L. Cavallari. (2017). Expert Review of Cardiovascular Therapy. Cited 9 times. https://doi.org/10.1080/14779072.2017.1355236

Pharmacists should jump onto the clinical pharmacogenetics train.

Julie A. Johnson. (2016). American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. Cited 9 times. https://doi.org/10.2146/AJHP160046

Genes affecting warfarin response—interactive or additive?

L. Cavallari, Julio D. Duarte. (2015). The Journal of Clinical Pharmacology. Cited 3 times. https://doi.org/10.1002/jcph.425

Clopidogrel pharmacogenetics: from evidence to implementation.

L. Cavallari, Julio D. Duarte. (2016). Future cardiology. Cited 1 times. https://doi.org/10.2217/fca-2016-0045